Clinical Trials · NCT06662539
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Zealand Pharma
- Enrollment
- 493
- Start date
- Dec 2024
- Locations
- 32 sites, 3 countries
- Primary endpoint
- Percent change from baseline in body weight to Week 28